HomeBUSINESS
BUSINESS

Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
(Oct.25.2017)

Eisai CEO Haruo Naito
An expanded collaboration with Biogen for its investigational anti-amyloid beta (Aβ) antibody aducanumab will provide Eisai with insights that could be leveraged for the development of other pipelines for Alzheimer’s disease, Haruo Naito, CEO of the Japanese pharma major, said on October 24 ...
(LOG IN FOR FULL STORY)

News Calendar